According to CoinMeta, Hengrui Medicine announced that the company and its subsidiaries have recently received the "Drug Clinical Trial Approval Notices" for six drugs issued by the National Medical Products Administration, including shr-4610 Injection, shr-9839 for injection (sc), shr-a2102 for injection, shr-4849 Injection, shr-7787 Injection, and hrs-4508 Tablets. Clinical trials are planned to be conducted in the near future. These drugs are intended for anti-tumor treatments, and as of now, the cumulative R&D investments for each project are approximately 16.8 million yuan, 128 million yuan, 455 million yuan, 101 million yuan, 72.6 million yuan, and 110 million yuan respectively (all unaudited). The drugs still need to complete clinical trials and pass review and approval before they can be launched on the market, which involves uncertainties.